Immunity from the measles vaccine declines significantly over time, with 18.1% of recipients lacking detectable antibodies 23 years after vaccination.
A study published Nov. 3 in eClinicalMedicine, the open access journal of The Lancet, by researchers from the University of Miami analyzed 18 studies involving 23,236 vaccinated individuals across 10 countries. The researchers found that the overall pooled seropositivity rate was 87.8%, with higher rates among those who received two or more doses (88.8%) compared to a single dose (84.3%).
Immunity declined steadily over time: 7.1% lacked antibodies 10 years after vaccination, 13% at 15 years, and 18.1% at 23 years or later. Each additional year post-vaccination was linked to a 5% decrease in the odds of being seropositive.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
